|Articles|August 31, 2006
QSV Biologics, Ltd. To Manufacture Synthetic Vitronectin for Tissue Therapies, Ltd.
Author(s)BioPharm International Editors
QSV Biologics, Ltd. (Edmonton, Canada, www.qsvbiologics.com) has signed a contract with Tissue Therapies Limited (Brisbane, Australia, www.tissuetherapies.com) for the cGMP manufacture of clinical quantities of synthetic Vitronectin (a component of the wound-healing treatment VitroGro) and a single-protein chimeric form of VitroGro.
Advertisement
QSV Biologics, Ltd. (Edmonton, Canada,
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Regulatory Challenges for Global Manufacturing of Vaccines
2
AI-Driven Organ-on-Chip Platforms Are Changing the Game in Bio/Pharma R&D
3
EU Biopharma Strategy: Scaling Up to Tackle Funding Gaps and Drive Innovation
4
Executive Summary: Charge Detection Mass Spectrometry (CDMS): From Complexity to Clarity – A New Era in Biomolecular Analysis
5
